Rabbit model with vascular balloon injury and diet-induced valve calcification

The combination of vascular balloon injury and dietary therapy with cholesterol and vitamin D2 in an animal model effectively induces aortic valve calcification, addressing the lack of suitable models and enabling the evaluation of therapeutic agents for this heart valve disease.

KR103046438B1Active Publication Date: 2026-11-11THE CATHOLIC UNIV OF KOREA IND ACADEMIC COOP FOUND +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020230005477
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2022-03-11
Filing Date
2023-01-13
Publication Date
2026-11-11
Estimated Expiration
2043-01-13

AI Technical Summary

Technical Problem

There is a lack of effective animal models for aortic valve calcification and insufficient methods to verify the clinical efficacy of potential treatments, hindering research on the pathogenesis and treatment of this common heart valve disease.

Method used

A method involving vascular balloon injury and a cholesterol diet supplemented with vitamin D2 is used to induce aortic valve calcification in an animal model, followed by treatment with a candidate substance and comparison with a control model to screen for therapeutic agents.

Benefits of technology

The method effectively induces valve calcification, increasing calcium accumulation, mineralization, macrophage infiltration, and fibrosis, providing a useful model for evaluating therapeutic agents.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112023005091745-PAT00008_ABST
    Figure 112023005091745-PAT00008_ABST
Patent Text Reader

Abstract

The present invention relates to a rabbit model involving valve calcification induced by vascular balloon injury and dietary therapy. It was confirmed that the combination of balloon injury and dietary therapy according to the present invention effectively induces valve calcification in rabbits, thereby inducing abnormal valve movement and increasing valve thickness. Furthermore, it was confirmed that it increases calcium accumulation within the valve and increases valve mineralization, and increases macrophage infiltration, thereby inducing valve damage. Additionally, it was confirmed that it promotes fibrosis within the valve, thereby increasing valve fibrosis. Thus, it was confirmed that the valve calcification induction method of the present invention is useful for creating valve damage and valve calcification models.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a rabbit model involving vascular balloon injury and valve calcification induced by diet. Background Technology

[0002] The heart has four valves that guide the flow of blood forward. Two of these are located in the left side of the heart, through which oxygenated blood flows, and the remaining two are located in the right side, through which deoxygenated blood flows. The valves on the left are the mitral valve and the aortic valve, while those on the right are the tricuspid valve and the pulmonary valve. The aortic valve is located between the left ventricle and the aorta and is designed to withstand the highest pressure. The aortic valve normally consists of three leaflets, but occasionally it may have two or four leaflets. Each leaflet is attached to the aortic wall by the aortic annulus, and there is a space between the aortic wall and the leaflet called the sinus of Valsalva. In the usual case where the aortic valve consists of three leaflets, they are referred to as the left coronary leaflet, the right coronary leaflet, and the uncoronary leaflet. The area where the aforementioned valve leaflets meet is called the commissure. Accordingly, in the case of a valve with three leaflets, three commissures exist near the aortic wall, and the center of each leaflet is called the apex. Each leaflet is not flat but, when viewed from the Valsalva sinus, has a concave shape in the center, resembling the shape of a rose petal. The aortic valve, the valve annulus, the aortic wall, and the Valsalva sinus between them are collectively referred to as the aortic root. Therefore, the aortic root is a trapezoidal cylinder, bordered at the bottom by the aortic annulus and at the top by the sinotubular junction, with the aortic valve leaflets located between them. Therefore, the aortic valve begins to open due to the twisting and tilting of the aortic muscle, fully opens as blood passes forward during left ventricular contraction, and then closes due to aortic pressure when the anterior blood flow decreases during left ventricular relaxation.

[0003] For the complete closure of the aortic valve, the diameter of the junction of the ascending aorta must be maintained to allow the valve leaflets to lean against each other; abnormal operation in this area can lead to aortic valve calcification. For instance, aortic valve calcification can be classified into cases where only isolated lesions exist in the valve leaflets themselves, cases involving lesions in the aortic root, and mixed lesions between these two extremes. In the early stages of aortic valve calcification, only lesions in the valve leaflets may be present; however, as time passes, it usually leads to structural deformation of the surrounding aortic root as well. Conversely, there are also cases where valve occlusion fails due to lesions in the aortic root. Aortic valve calcification is one of the most common heart valve diseases, and its incidence is gradually increasing with the rise in the elderly population. Aortic valve calcification can progress to aortic valve sclerosis and then to aortic valve stenosis.

[0004] Methods for treating aortic valve calcification include valve replacement, which involves fabricating and surgically inserting an artificial valve, and recently, reconstructive surgery to repair the valve for continued use. However, considering the inherent risks of the surgery itself and potential postoperative issues, there is a need to develop substances capable of inhibiting aortic valve calcification. Yet, there is a lack of models that effectively account for aortic valve calcification, and even if appropriate treatments are sought, there is currently a shortage of methods to concretely verify their clinical efficacy.

[0005] Therefore, in order to clearly understand the pathogenesis of aortic valve calcification and to conduct in-depth research on related diseases, it is essential to secure a large number of animal models involving aortic valve calcification and possess a significant amount of experimental data. The problem to be solved

[0006] The object of the present invention is a step of stimulating a valve with a balloon injury in an animal model; and

[0007] The present invention provides a method for producing an animal model of aortic valve calcification, comprising the step of feeding a cholesterol diet and vitamin D2 to an animal model in which the valve is stimulated by the above-mentioned balloon injury.

[0008] Another objective of the present invention is to provide an animal model of aortic valve calcification produced by the above method.

[0009] Another objective of the present invention is to provide a step of treating the above animal model with a candidate substance; and

[0010] The present invention provides a screening method for a therapeutic agent for aortic valve calcification, comprising the step of comparing the degree of valve calcification in an animal model treated with the above-mentioned candidate substance with that of a control animal model. means of solving the problem

[0011] To achieve the above objective, the present invention comprises the steps of: stimulating a valve with a balloon injury in an animal model; and

[0012] A method for producing an animal model of aortic valve calcification is provided, comprising the step of feeding a cholesterol diet and vitamin D2 to an animal model in which the valve is stimulated by the above balloon injury.

[0013] In addition, the present invention provides an animal model of aortic valve calcification produced by the above method.

[0014] In addition, the present invention comprises the step of treating the above animal model with a candidate substance; and

[0015] The present invention provides a screening method for a therapeutic agent for aortic valve calcification, comprising the step of comparing the degree of valve calcification in an animal model treated with the above-mentioned candidate substance with that of a control animal model. Effects of the invention

[0016] It was confirmed that the combination of balloon injury and dietary therapy according to the present invention effectively induces valve calcification in an animal model, thereby inducing abnormal valve movement and increasing valve thickness. Furthermore, it was confirmed that it increases calcium accumulation within the valve and increases valve mineralization, and increases macrophage infiltration, thereby inducing valve damage. Additionally, it was confirmed that it promotes fibrosis within the valve, thereby increasing valve fibrosis. Thus, it was confirmed that the valve calcification induction method of the present invention promotes valve damage and valve calcification, and can be usefully utilized in related industries. Brief explanation of the drawing

[0017] Figure 1 shows the surgical procedure of a rabbit inducing a balloon injury according to the present invention. Figure 2 illustrates the process of producing a rabbit with balloon injury and dietary therapy in combination according to the present invention. Figure 3 is a figure showing changes in the aortic valve of a rabbit treated with balloon injury and dietary therapy according to the present invention, confirmed by Eco-cardiography. Figure 4 shows the calcium accumulation in the aortic valve of each individual in the control group of rabbits that underwent dietary therapy, confirmed by Alizarin Red staining. Figure 5 shows the histological changes and macrophage infiltration of the aortic valves of each individual in the control group of rabbits that underwent dietary therapy, confirmed by Von Kossa staining and histochemical staining. Figure 6 is a figure showing the calcium accumulation in the aortic valve of each individual in a group of rabbits treated with the balloon injury and dietary therapy of the present invention, confirmed by Alizarin Red staining. Figure 7 is a figure showing the histological changes and macrophage infiltration of each individual in a group of rabbits treated with balloon injury and dietary therapy according to the present invention, confirmed by Von Kossa staining and histochemical staining. FIG. 8 is a figure showing the histological changes of each individual in a group of rabbits treated with balloon injury and dietary therapy according to the present invention, confirmed by MT, Alizarin Red, and Von Kossa staining (A: MT staining result, B: Alizarin Red staining result, C: Von Kossa staining result). Specific details for implementing the invention

[0018] Embodiments of the present invention will be described in detail below with reference to the attached drawings. In the following description, detailed descriptions of technologies well known to those skilled in the art may be omitted. Furthermore, in describing the present invention, detailed descriptions of related known functions or configurations may be omitted if it is determined that such descriptions would unnecessarily obscure the essence of the present invention. Additionally, the terminology used in this specification is used to appropriately express preferred embodiments of the present invention, and may vary depending on the intent of the user or operator, or the conventions of the field to which the present invention belongs.

[0019] Therefore, the definitions of these terms should be based on the content throughout this specification. Throughout the specification, when a part is described as "comprising" a certain component, this means that, unless specifically stated otherwise, it does not exclude other components but may include additional components.

[0020] The present invention comprises the steps of: stimulating a valve with a balloon injury in an animal model; and

[0021] A method for producing an animal model of aortic valve calcification is provided, comprising the step of feeding a cholesterol diet and vitamin D2 to an animal model in which the valve is stimulated by the above balloon injury.

[0022] In addition, the present invention provides an animal model of aortic valve calcification produced by the above method.

[0023] According to one embodiment of the present invention, the balloon damage may induce damage to the aortic valve, and the balloon damage may be induced by balloon inflation at 5 to 6 atmospheres (atm) and by balloon inflation 1 to 10 times.

[0024] According to one embodiment of the present invention, the cholesterol diet may contain cholesterol in a weight ratio of 0.1 to 1.0.

[0025] According to one embodiment of the present invention, the vitamin D2 may be supplied in an amount of 25,000 to 75,000 units of vitamin D2.

[0026] According to one embodiment of the present invention, the cholesterol diet and vitamin D2 may be administered for 5 to 10 weeks, preferably for 7 to 9 weeks, but are not limited thereto.

[0027] According to one embodiment of the present invention, the animal model may have increased valve calcification compared to the reference value of the control group, and the valve calcification may be an increase in calcium accumulation within the valve and an increase in valve mineralization.

[0028] According to one embodiment of the present invention, the animal model may have increased valve damage compared to the reference value of the control group, said valve damage may be increased macrophage infiltration within the valve, and said increased macrophage infiltration may be increased expression of RAM11.

[0029] According to one embodiment of the present invention, the valve damage may be an increase in valve fibrosis.

[0031] In addition, the present invention provides an animal model of aortic valve calcification produced by the above method.

[0033] In addition, the present invention comprises the step of treating the above animal model with a candidate substance; and

[0034] The present invention provides a screening method for a therapeutic agent for aortic valve calcification, comprising the step of comparing the degree of valve calcification in an animal model treated with the above-mentioned candidate substance with that of a control animal model.

[0035] According to one embodiment of the present invention, the candidate substance may reduce calcium accumulation in the valve compared to a reference value of the control group.

[0036] According to one embodiment of the present invention, the candidate substance may reduce valve mineralization compared to a reference value of a control group.

[0037] According to one embodiment of the present invention, the candidate substance may reduce macrophage infiltration within the valve compared to a reference value of the control group, and reducing macrophage infiltration may reduce the expression of RAM11.

[0038] According to one embodiment of the present invention, the candidate substance may reduce valve fibrosis compared to a reference value of a control group.

[0040] The present invention will be explained in more detail below through examples. These examples are merely for the purpose of explaining the present invention more specifically, and it will be obvious to those skilled in the art that the scope of the present invention is not limited to these examples.

[0042] <Example 1> Vascular balloon injury and dietary therapy

[0043] To construct the animal model of valve calcification induced by the present invention, vascular balloon injury and dietary therapy were performed in combination. Specifically, after stabilizing a 3 to 4 kg New Zealand white rabbit, the rabbit was intramuscularly anesthetized with Zolletil (15 mg / kg) and Xylazine (5 mg / kg) on ​​the day of the experiment (Day 0). Subsequently, an incision approximately 3 cm in length was made in the skin of the neck, and after identifying the left carotid artery and left ventricle, a guide wire was inserted into the left ventricle using an IV catheter. Then, an 8 mm diameter vascular balloon was positioned along the guide wire and used to induce injury to the rabbit aortic valve. After inserting the vascular balloon, stimulation was applied five times using the balloon inflated to 6 atmospheres (atm) at the valve location. After repeating the above stimulation process, the incision was closed with sutures, disinfected, and allowed to recover (Fig. 1). Experimental rabbits (chol+VitD2+Balloon or HC+VitD2+Balloon) were prepared by continuously maintaining a diet of 0.5% cholesterol + 50,000 Unit / day vitamin D2 for 8 weeks (Fig. 2). As the control group, rabbits (chol+VitD2 or HC+VitD2) fed only a diet of 0.5% cholesterol + 50,000 IU / day vitamin D2 without balloon injury stimulation were used, and 3 rabbits were used per group. As the normal control group, rabbits that received no treatment were used.

[0045] <Example 2> Confirmation of valve calcification

[0046] To confirm the valve calcification of the valve calcification rabbit model prepared in Example 1 above, the rabbit heart was photographed by Eco-cardiography at week 8 after the start of the experiment.

[0048] As a result, as shown in Figure 3, Eco-cardiography analysis confirmed that the control group rabbits (chol+VitD2) showed increased abnormalities in valve movement and increased valve thickness compared to the normal control group (control), and the experimental group rabbits of the present invention (chol+VitD2+Balloon) showed even greater abnormalities in valve movement and increased valve thickness compared to the control group rabbits (chol+VitD2), confirming that valve calcification was accelerated.

[0050] <Example 3> Histological Analysis

[0051] <3-1> Histological Analysis 1 (Confirmation of Calcium Accumulation and RAM11 Expression)

[0052] The animal models prepared in Example 1 above were humanely sacrificed, and the aortic portion was excised. The valves were stained with Alizarin red to check the degree of calcium accumulation. Additionally, to check the degree of valve calcification, von Kossa staining was performed to confirm tissue mineralization. Furthermore, to check for macrophage infiltration within the valves, the expression of RAM11, a macrophage marker, was analyzed by immunohistochemical staining.

[0054] As a result, as shown in Figures 4 and 5, it was confirmed that calcium accumulation and tissue mineralization occurred in only some rabbits in the control group (chol+VitD2). In addition, it was confirmed that the expression of RAM11 within the valve also varied by individual, indicating that different valve damage was induced in each individual.

[0055] Compared to the control group rabbits mentioned above, as shown in Figures 6 and 7, in the experimental group rabbits of the present invention (chol+VitD2+Balloon), it was confirmed that calcium accumulation within the valve and tissue mineralization progressed in each individual, and that RAM11 expression was also expressed in all rabbits, thus confirming that the valve calcification induction method of the present invention effectively induces valve calcification in rabbits.

[0057] <3-2> Histological Analysis 2 (Identification of Histological Changes)

[0058] The animal models prepared in Example 1 above were humanely sacrificed, the aortic valve portion was excised, and the histological changes were evaluated. Specifically, tissue damage was confirmed by staining with Masson's trichrome (MT) stain, which can confirm infarction or fibrosis within the tissue, and Alizarin red and von Kossa staining were performed, respectively, in the same manner as in Example 3-1 above to further confirm histological changes.

[0060] As a result, as shown in Fig. 8, compared to the control group, fibrosis within the valve increased in the HC+VitD2 group, but in the HC+VitD2+Balloon group of the present invention, fibrosis within the valve increased significantly, confirming that valve damage was induced. In addition, as in Example 3-1 above, mineralization within the valve and calcium accumulation also increased significantly in the HC+VitD2+Balloon group, confirming that the valve calcification induction method of the present invention effectively induces valve damage and valve calcification in rabbits.

[0062] Accordingly, it was confirmed that the combination of balloon injury and dietary therapy according to the present invention effectively induces valve calcification in rabbits, thereby inducing abnormal valve movement and increasing valve thickness. Furthermore, it was confirmed that it increases calcium accumulation within the valve and increases valve mineralization, and increases macrophage infiltration, thereby inducing valve damage. Additionally, it was confirmed that it promotes fibrosis within the valve, thereby increasing valve fibrosis, thus confirming that the valve calcification induction method of the present invention is useful for creating valve damage and valve calcification models.

Claims

Claim 1 A method for producing an animal model of aortic valve calcification, comprising: a step of stimulating the valve of an animal model with a balloon injury; and a step of feeding a cholesterol diet and vitamin D2 to the animal model in which the valve is stimulated by the balloon injury; wherein the balloon injury is induced by inflating the balloon 4 to 6 times at 5 to 7 atmospheres (atm) within the left ventricle; wherein the cholesterol diet and vitamin D2 are fed for 7 to 9 weeks; wherein the cholesterol diet contains 0.4 to 0.6% cholesterol and the vitamin D2 is supplied at a dose of 45,000 to 55,000 IU / day; wherein the animal model has increased calcium accumulation within the valve, progressing tissue mineralization, increased expression of RAM11, and increased valve fibrosis. Claim 2 In claim 1, the balloon injury is a method that induces damage to the aortic valve. Claim 3 delete Claim 4 delete Claim 5 delete Claim 6 delete Claim 7 delete Claim 8 delete Claim 9 delete Claim 10 delete Claim 11 delete Claim 12 delete Claim 13 delete Claim 14 delete Claim 15 An animal model of aortic valve calcification produced by the method of claim 1, wherein the animal model has increased calcium accumulation within the valve, progressing tissue mineralization, and increased expression of RAM11, and wherein the animal model has increased valve fibrosis. Claim 16 A method for screening therapeutic agents for aortic valve calcification, comprising: a step of treating an animal model of claim 15 with a candidate substance; and a step of comparing the degree of valve calcification in the animal model treated with the candidate substance with that of a control animal model; wherein the candidate substance reduces calcium accumulation within the valve, inhibits tissue mineralization, reduces the expression of RAM11, and reduces valve fibrosis. Claim 17 delete Claim 18 delete Claim 19 delete Claim 20 delete Claim 21 delete